Abridge vs DeepScribe
Both sides of this pairing hold A grades on evidence and EHR depth, so the split is scope against specialty. Abridge is the enterprise reference standard: Best in KLAS for Ambient AI in 2025 and 2026, the largest independent peer reviewed study in the category with 1,306 clinicians at Kaiser Permanente published in NEJM AI, native Epic depth across Haiku, Canto, and Hyperdrive, and coverage spanning more than 55 specialties across outpatient, inpatient, and emergency settings. DeepScribe went deep instead of wide: oncology is its center of gravity with a reported 40 percent of US cancer care visits, tuned models for six further specialties, and the highest independent rating in the lane at 98.8 on the KLAS Emerging Company Spotlight. If your failure mode is a system wide rollout across settings that compliance must be able to audit, start with Abridge. If your failure mode is complex specialty documentation that generalist scribes get wrong, oncology above all, start with DeepScribe. Neither publishes pricing.
- The evidence bar decides it: the largest independent peer reviewed study in the category, 1,306 clinicians at Kaiser Permanente published in NEJM AI, corroborated by Best in KLAS for Ambient AI in both 2025 and 2026, which is buyer survey based rather than vendor asserted.
- Compliance needs an audit trail: Linked Evidence maps every part of a generated note back to the source audio so a clinician can verify any sentence against what was said before signing, a control DeepScribe does not document.
- Setting breadth is the requirement: more than 28 languages and 55 specialties across outpatient, inpatient, and emergency settings, with native Epic embedding extending into structured orders and real time prior authorization.
- Specialty depth is the requirement: oncology first with a reported 5 million oncology visits a year and roughly 40 percent of US cancer care visits documented, plus tuned models for cardiology, urology, gastroenterology, orthopedics, neurology, and nephrology.
- The independent rating is the strongest in the lane: a 98.8 KLAS Emerging Company Spotlight score with A plus marks across all six measured categories, plus 2025 KLAS Top 5 rankings and an August 2025 Journal of Clinical Pathways study in oncology.
- Longitudinal chart awareness: reads problems, medications, labs, and prior notes before the encounter and writes structured data into discrete EHR fields after, with HCC, CPT, and ICD-10 suggestions built into the note.
Side-by-Side
| Axis | A Abridge |
D DeepScribe |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | |
| Model and Technology Transparency | — | — |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | — |
| HIPAA and BAA Posture | — | — |
| Security Certifications and Trust Center | — | — |
| FDA and Regulatory Status | — | — |
| AI Governance and Bias Disclosure | — | — |
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | — | — |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Deployment counts and market share figures for both vendors are vendor published, including Abridge's 250 plus health systems and DeepScribe's oncology share. Both evidence grades reflect the scale, venue, and independence of the cited studies and ratings rather than a re verification of their findings, and the KLAS instruments differ: Best in KLAS category awards for Abridge against the Emerging Company Spotlight for DeepScribe. Neither vendor publishes pricing. Third party estimates recorded in this index place Abridge near $2,500 per clinician per year and DeepScribe at $350 to $500 per provider per month, with some reports near $750; all are unconfirmed estimates.